VivoSim Labs (VIVS) Total Non-Current Liabilities (2011 - 2014)
VivoSim Labs (VIVS) posted quarterly Total Non-Current Liabilities of $1.5 million for Q1 2014, up 1.13% year-over-year from $1.5 million in Q1 2013, and down 20.07% quarter-over-quarter from $1.9 million in Q4 2013.
VivoSim Labs (VIVS) Total Non-Current Liabilities (2011 - 2014) Analysis & Trends
VivoSim Labs' Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $1.5 million for Q1 2014.
- In Q1 2014, Total Non-Current Liabilities rose 1.13% year-over-year to $1.5 million; the TTM figure through Mar 2014 stood at $1.5 million (up 1.13% YoY), while the FY2014 annual figure was $1.5 million, up 1.13% from the prior year.
- Total Non-Current Liabilities for Q1 2014 stood at $1.5 million, down from $1.9 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $2.2 million in Q3 2013, with the low at -$1.0 million in Q3 2012.
- The 4-year median for Total Non-Current Liabilities is $1.5 million (2013), against an average of $1.3 million.
- The sharpest annual moves came in 2012 and 2013: Total Non-Current Liabilities fell 27.52% in 2012, then surged 315.23% in 2013.
- VivoSim Labs' Total Non-Current Liabilities stood at $2.0 million in 2011, then fell by 27.52% to $1.4 million in 2012, then jumped by 33.15% to $1.9 million in 2013, then decreased by 20.07% to $1.5 million in 2014.
- Business Quant data shows VIVS's Total Non-Current Liabilities at $1.5 million in Q1 2014, $1.9 million in Q4 2013, and $2.2 million in Q3 2013.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2014 | 1.53 Mn |
| Dec 31, 2013 | 1.91 Mn |
| Sep 30, 2013 | 2.16 Mn |
| Mar 31, 2013 | 1.51 Mn |
| Dec 31, 2012 | 1.43 Mn |
| Sep 30, 2012 | -1.00 Mn |
| Jun 30, 2012 | 889,006.00 |
| Mar 31, 2012 | 1.11 Mn |
| Dec 31, 2011 | 1.98 Mn |